The nuclear receptor AhR controls bone homeostasis by regulating osteoclast differentiation via the RANK/c-fos signaling axis

Journal of Immunology

Volumn 197, Issue 12, 2016, Pages 4639-4650

  Izawa, Takashi ^a   Arakaki, Rieko ^a   Mori, Hiroki ^a   Tsunematsu, Takaaki ^a   Kudo, Yasusei ^a   Tanaka, Eiji ^a   Ishimaru, Naozumi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BENZO[A]PYRENE; CATHEPSIN K; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NFAT CYTOPLASMIC CALCINEURIN DEPENDENT 1; PROTEIN C FOS; PROTEIN KINASE B; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; BENZO[A]PYRENE DERIVATIVE; OSTEOCLAST DIFFERENTIATION FACTOR; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE HOMEOSTASIS; BONE MARROW; CELL DIFFERENTIATION; CONTROLLED STUDY; ENCHONDRAL OSSIFICATION; ENZYME PHOSPHORYLATION; FRACTURE HEALING; GENE EXPRESSION; HOMEOSTASIS; IN VITRO STUDY; MACROPHAGE; MITOCHONDRIAL BIOGENESIS; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BONE DEVELOPMENT; BONE MARROW CELL; C57BL MOUSE; CELL CULTURE; GENETICS; KNOCKOUT MOUSE; METABOLISM; MITOCHONDRION; PHYSIOLOGY;

ANIMALS; BENZOPYRENES; BONE MARROW CELLS; CELLS, CULTURED; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOCHONDRIA; NF-KAPPA B; OSTEOCLASTS; OSTEOGENESIS; PROTO-ONCOGENE PROTEINS C-FOS; RANK LIGAND; RECEPTORS, ARYL HYDROCARBON; SIGNAL TRANSDUCTION;

EID: 85002180250     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600822     Document Type: Article

References (55)

1. Fujii-Kuriyama, Y., and J. Mimura. 2005. Molecular mechanisms of AhR functions in the regulation of cytochrome P450 genes. Biochem. Biophys. Res. Commun. 338: 311-317.
2. Mimura, J., and Y. Fujii-Kuriyama. 2003. Functional role of AhR in the expression of toxic effects by TCDD. Biochim. Biophys. Acta 1619: 263-268.
3. Naruse, M., Y. Ishihara, S. Miyagawa-Tomita, A. Koyama, and H. Hagiwara. 2002. 3-Methylcholanthrene, which binds to the arylhydrocarbon receptor, inhibits proliferation and differentiation of osteoblasts in vitro and ossification in vivo. Endocrinology 143: 3575-3581.
4. Petrulis, J. R., and G. H. Perdew. 2002. The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem. Biol. Interact. 141: 25-40.
5. Novack, D. V., and S. L. Teitelbaum. 2008. The osteoclast: friend or foe? Annu. Rev. Pathol. 3: 457-484.
6. Teitelbaum, S. L. 2000. Bone resorption by osteoclasts. Science 289: 1504-1508.
7. Wada, T., T. Nakashima, N. Hiroshi, and J. M. Penninger. 2006. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med. 12: 17-25.
8. Takayanagi, H. 2007. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7: 292-304.
9. Wagner, E. F., and K. Matsuo. 2003. Signalling in osteoclasts and the role of Fos/ AP1 proteins. Ann. Rheum. Dis. 62(Suppl. 2): ii83-ii85.
10. Matsuo, K., J. M. Owens, M. Tonko, C. Elliott, T. J. Chambers, and E. F.Wagner. 2000. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat. Genet. 24: 184-187.
11. Iqbal, J., L. Sun, J. Cao, T. Yuen, P. Lu, I. Bab, N. A. Leu, S. Srinivasan, S. Wagage, C. A. Hunter, et al. 2013. Smoke carcinogens cause bone loss through the aryl hydrocarbon receptor and induction of Cyp1 enzymes. Proc. Natl. Acad. Sci. USA 110: 11115-11120.
12. Yu, T. Y., T. Kondo, T. Matsumoto, Y. Fujii-Kuriyama, and Y. Imai. 2014. Aryl hydrocarbon receptor catabolic activity in bone metabolism is osteoclast dependent in vivo. Biochem. Biophys. Res. Commun. 450: 416-422.
13. Yu, T. Y., W. J. Pang, and G. S. Yang. 2015. Aryl hydrocarbon receptors in osteoclast lineage cells are a negative regulator of bone mass. PLoS One 10: e0117112.
14. Wejheden, C., S. Brunnberg, S. Larsson, P. M. Lind, G. Andersson, and A. Hanberg. 2010. Transgenic mice with a constitutively active aryl hydrocarbon receptor display a gender-specific bone phenotype. Toxicol. Sci. 114: 48-58.
15. Pitts, Jr., J. N., K. A. Van Cauwenberghe, D. Grosjean, J. P. Schmid, D. R. Fitz, W. L. Belser, G. P. Knudson, and P. M. Hynds. 1978. Atmospheric reactions of polycyclic aromatic hydrocarbons: facile formation of mutagenic nitro derivatives. Science 202: 515-519.
16. Hankinson, O. 2005. Role of coactivators in transcriptional activation by the aryl hydrocarbon receptor. Arch. Biochem. Biophys. 433: 379-386.
17. Martin, L. A., S. K. Byrd, and R. E. Milofsky. 2003. Rapid communication: effects of tobacco processing on the quantity of benzo[a]pyrene in mainstream smoke. J. Toxicol. Environ. Health A 66: 1283-1286.
18. Besaratinia, A., J. C. Kleinjans, and F. J. Van Schooten. 2002. Biomonitoring of tobacco smoke carcinogenicity by dosimetry of DNA adducts and genotyping and phenotyping of biotransformational enzymes: a review on polycyclic aromatic hydrocarbons. Biomarkers 7: 209-229.
19. Szulc, P., P. Garnero, B. Claustrat, F. Marchand, F. Duboeuf, and P. D. Delmas. 2002. Increased bone resorption in moderate smokers with low body weight: the Minos study. J. Clin. Endocrinol. Metab. 87: 666-674.
20. Rapuri, P. B., J. C. Gallagher, K. E. Balhorn, and K. L. Ryschon. 2000. Smoking and bone metabolism in elderly women. Bone 27: 429-436.
21. Porter, S. E., and E. N. Hanley, Jr. 2001. The musculoskeletal effects of smoking. J. Am. Acad. Orthop. Surg. 9: 9-17.
22. McKee, M. D., D. J. DiPasquale, L. M. Wild, D. J. Stephen, H. J. Kreder, and E. H. Schemitsch. 2003. The effect of smoking on clinical outcome and complication rates following Ilizarov reconstruction. J. Orthop. Trauma 17: 663-667.
23. Hosoya, T., N. Harada, J. Mimura, H. Motohashi, S. Takahashi, O. Nakajima, M. Morita, S. Kawauchi, M. Yamamoto, and Y. Fujii-Kuriyama. 2008. Inducibility of cytochrome P450 1A1 and chemical carcinogenesis by benzo[a]pyrene in AhR repressor-deficient mice. Biochem. Biophys. Res. Commun. 365: 562-567.
24. Faccio, R., W. Zou, G. Colaianni, S. L. Teitelbaum, and F. P. Ross. 2003. High dose M-CSF partially rescues the Dap122/2 osteoclast phenotype. J. Cell. Biochem. 90: 871-883.
25. Takeshita, S., K. Kaji, and A. Kudo. 2000. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J. Bone Miner. Res. 15: 1477-1488.
26. Sekine, H., J. Mimura, M. Oshima, H. Okawa, J. Kanno, K. Igarashi, F. J. Gonzalez, T. Ikuta, K. Kawajiri, and Y. Fujii-Kuriyama. 2009. Hypersensitivity of aryl hydrocarbon receptor-deficient mice to lipopolysaccharideinduced septic shock. Mol. Cell. Biol. 29: 6391-6400.
27. Kitamura, T., Y. Koshino, F. Shibata, T. Oki, H. Nakajima, T. Nosaka, and H. Kumagai. 2003. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp. Hematol. 31: 1007-1014.
28. Teitelbaum, S. L. 2007. Osteoclasts: what do they do and how do they do it? Am. J. Pathol. 170: 427-435.
29. Feng, X. 2005. Regulatory roles and molecular signaling of TNF family members in osteoclasts. Gene 350: 1-13.
30. Matsuo, K., D. L. Galson, C. Zhao, L. Peng, C. Laplace, K. Z. Wang, M. A. Bachler, H. Amano, H. Aburatani, H. Ishikawa, and E. F. Wagner. 2004. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J. Biol. Chem. 279: 26475-26480.
31. Asagiri, M., and H. Takayanagi. 2007. The molecular understanding of osteoclast differentiation. Bone 40: 251-264.
32. Grigoriadis, A. E., Z. Q. Wang, M. G. Cecchini, W. Hofstetter, R. Felix, H. A. Fleisch, and E. F. Wagner. 1994. c-Fos: a key regulator of osteoclastmacrophage lineage determination and bone remodeling. Science 266: 443-448.
33. Tsuji, N., K. Fukuda, Y. Nagata, H. Okada, A. Haga, S. Hatakeyama, S. Yoshida, T. Okamoto, M. Hosaka, K. Sekine, et al. 2014. The activation mechanism of the aryl hydrocarbon receptor (AhR) by molecular chaperone HSP90. FEBS Open Bio 4: 796-803.
34. Ishii, K. A., T. Fumoto, K. Iwai, S. Takeshita, M. Ito, N. Shimohata, H. Aburatani, S. Taketani, C. J. Lelliott, A. Vidal-Puig, and K. Ikeda. 2009. Coordination of PGC-1b and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat. Med. 15: 259-266.
35. Wei, W., X. Wang, M. Yang, L. C. Smith, P. C. Dechow, J. Sonoda, R. M. Evans, and Y. Wan. 2010. PGC1b mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab. 11: 503-516.
36. Wan, Y., L. W. Chong, and R. M. Evans. 2007. PPAR-g regulates osteoclastogenesis in mice. Nat. Med. 13: 1496-1503.
37. Zeng, R., R. Faccio, and D. V. Novack. 2015. Alternative NF-kB regulates RANKL-induced osteoclast differentiation and mitochondrial biogenesis via independent mechanisms. J. Bone Miner. Res. 30: 2287-2299.
38. Le, A. X., T. Miclau, D. Hu, and J. A. Helms. 2001. Molecular aspects of healing in stabilized and non-stabilized fractures. J. Orthop. Res. 19: 78-84.
39. Teti, A. 2013. Mechanisms of osteoclast-dependent bone formation. Bonekey Rep. 2:449.
40. Karsdal, M. A., T. J. Martin, J. Bollerslev, C. Christiansen, and K. Henriksen. 2007. Are nonresorbing osteoclasts sources of bone anabolic activity? J. Bone Miner. Res. 22: 487-494.
41. Takeshita, S., T. Fumoto, K. Matsuoka, K. A. Park, H. Aburatani, S. Kato, M. Ito, and K. Ikeda. 2013. Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation. J. Clin. Invest. 123: 3914-3924.
42. Nguyen, N. T., A. Kimura, T. Nakahama, I. Chinen, K. Masuda, K. Nohara, Y. Fujii-Kuriyama, and T. Kishimoto. 2010. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl. Acad. Sci. USA 107: 19961-19966.
43. Kimura, A., T. Naka, T. Nakahama, I. Chinen, K. Masuda, K. Nohara, Y. Fujii- Kuriyama, and T. Kishimoto. 2009. Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J. Exp. Med. 206: 2027-2035.
44. Takayanagi, H., S. Kim, T. Koga, H. Nishina, M. Isshiki, H. Yoshida, A. Saiura, M. Isobe, T. Yokochi, J. Inoue, et al. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3: 889-901.
45. Kung, M. H., K. Yukata, R. J. O'Keefe, and M. J. Zuscik. 2012. Aryl hydrocarbon receptor-mediated impairment of chondrogenesis and fracture healing by cigarette smoke and benzo(a)pyrene. J. Cell. Physiol. 227: 1062-1070.
46. Kim, M. S., Y. M. Yang, A. Son, Y. S. Tian, S. I. Lee, S. W. Kang, S. Muallem, and D. M. Shin. 2010. RANKL-mediated reactive oxygen species pathway that induces long lasting Ca2+ oscillations essential for osteoclastogenesis. J. Biol. Chem. 285: 6913-6921.
47. Lelliott, C. J., G. Medina-Gomez, N. Petrovic, A. Kis, H. M. Feldmann, M. Bjursell, N. Parker, K. Curtis, M. Campbell, P. Hu, et al. 2006. Ablation of PGC-1b results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performance. PLoS Biol. 4: e369.
48. Vianna, C. R., M. Huntgeburth, R. Coppari, C. S. Choi, J. Lin, S. Krauss, G. Barbatelli, I. Tzameli, Y. B. Kim, S. Cinti, et al. 2006. Hypomorphic mutation of PGC-1b causes mitochondrial dysfunction and liver insulin resistance. Cell Metab. 4: 453-464.
49. Sonoda, J., I. R. Mehl, L. W. Chong, R. R. Nofsinger, and R. M. Evans. 2007. PGC-1b controls mitochondrial metabolism to modulate circadian activity, adaptive thermogenesis, and hepatic steatosis. Proc. Natl. Acad. Sci. USA 104: 5223-5228.
50. Arany, Z., N. Lebrasseur, C. Morris, E. Smith, W. Yang, Y. Ma, S. Chin, and B. M. Spiegelman. 2007. The transcriptional coactivator PGC-1b drives the formation of oxidative type IIX fibers in skeletal muscle. Cell Metab. 5: 35-46.
51. Zhou, Y., H. Y. Tung, Y. M. Tsai, S. C. Hsu, H. W. Chang, H. Kawasaki, H. C. Tseng, B. Plunkett, P. Gao, C. H. Hung, et al. 2013. Aryl hydrocarbon receptor controls murine mast cell homeostasis. Blood 121: 3195-3204.
52. Nakahama, T., A. Kimura, N. T. Nguyen, I. Chinen, H. Hanieh, K. Nohara, Y. Fujii-Kuriyama, and T. Kishimoto. 2011. Aryl hydrocarbon receptor deficiency in T cells suppresses the development of collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 108: 14222-14227.
53. Di Meglio, P., J. H. Duarte, H. Ahlfors, N. D. Owens, Y. Li, F. Villanova, I. Tosi, K. Hirota, F. O. Nestle, U. Mrowietz, et al. 2014. Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity 40: 989-1001.
54. Gerstenfeld, L. C., T. J. Cho, T. Kon, T. Aizawa, A. Tsay, J. Fitch, G. L. Barnes, D. T. Graves, and T. A. Einhorn. 2003. Impaired fracture healing in the absence of TNF-a signaling: the role of TNF-a in endochondral cartilage resorption. J. Bone Miner. Res. 18: 1584-1592.
55. Zhang, X., E. M. Schwarz, D. A. Young, J. E. Puzas, R. N. Rosier, and R. J. O'Keefe. 2002. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J. Clin. Invest. 109: 1405-1415.